Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 1

Interventions

pembrolizumab 1270Specimen Handling 921Magnetic Resonance Spectroscopy 832Carboplatin 829Cyclophosphamide 802Cisplatin 726Nivolumab 682Paclitaxel 639Radiotherapy 613Gemcitabine 578Biopsy 556Bevacizumab 477Dexamethasone 445fludarabine 405Docetaxel 382venetoclax 372Oxaliplatin 365Capecitabine 360Fluorouracil 358atezolizumab 345durvalumab 338Rituximab 336Drug Therapy 330Doxorubicin 319Radiosurgery 316Blood Specimen Collection 313Pemetrexed 308Standard of Care 306Ipilimumab 305Radiation 285

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Benchmarking × 1 year × Clear all
NCT04729322 2025-12-23

Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
15 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡